Alterity Therapeutics: Half Yearly Report and Accounts
Filed with ASX · · 27 pages · English
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
- Quarterly Activities/Appendix 4C Cash Flow Report
- Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
- Alterity Board Changes
- Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference
Later from Alterity Therapeutics
- Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
- Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
- Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
- Alterity Receives Positive FDA Feedback From Type C Meeting
- Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics